确定抵抗治疗结肠癌药物的原因已阅

1、确定抵抗治疗结肠癌药物的原因identified a cause of resista nee to colon cancer treatmentthe work will be published in the latest issue of nature medici ne journaldoctors and researchers of hospital del mar and its research institute, the imim, have lead a study describing a new pharmacological resistance to cancer

2、. this new mechanism is a mutation in an oncogene called egfr (epidermal growth factor receptor) causi ng resista nee to treatment using a drug called cetuximab, a monoclonal antibody which specifically attacks the egfr.the study proves that, both in lab models and in patients with colon cancer, thi

3、s mutation appears during the disease and that, when this happens, it stops the drug from being effective and the tumor grows. this fin ding will benefit a large nu mber of patients since colorectal cancer is the second most frequent tumor and cetuximab is a drug used regularly to treat this form of

4、 cancer.also, another extremely relevant fact is that tumors acquire this mutation do respond to a treatment using another similar drug, called panitumumab, which is also available for clinical use. this carries im porta nt clinical implications, since it suggests the possibility of carrying out cli

5、nical tests to confirm the effectiveness of panitumumab in patients with colon cancer who no ion ger resp ond to cetuximab, this increasi ng the range of therapies that may be used on patients with this cancer.the relevance of this study is also in the fact that it is the first time that a mutation

6、is detected in the field of oncology instead of a bond with the antibody as a form of resistance therefore, it will be interesting to see whether there are other similar mutations causing resistance to other pharmacological antibodies which are used frequently to treat other forms of cancer, such as

7、 breast cancer.therefore, this is a completely new mechanism of resista nee to a drug used very often for a type of cancer with a high in cide nee and releva nt clinical implicatio ns for the treatment of patients with this type of cancer.”the discovery of this mutation may explain, at a molecular l

8、evel, the benefits obtained by some patients with colon cancer treated with panitumumab and the inefficiency when treating with cetuximab'* explains clara montagut, an associate doctor of the oncology service of hospital del mar and a researcher at imim, who has lead this study.colorectal cancer

9、 is the most frequent form of cancer in men and wome n and shows an in creasing in cidence, and is the main cause of death by cancer when studying the cases in male and female patients jointly. however, over the past decade, treatme nt has bee n revolutionized with the introduction of new chemothera

10、py drugs and treatments targeti ng cellular targets, such as mono clonal antibodies or drugs used to treat colorectal cancer. dr. joan albanell, head of the medical oncologic service of hospital del mar and head of the research group and the author of the study, states that: ”this new type of mutati

11、on reveals one of the causes why cancer therapy with monoclonal antibodies may cease to be effective at a given moment and, especially, opens the door to looking for solutions.”dr. montagut concludes by saying: hthese results justify developing tests to detect this mutation in patients that are bein

12、g treated with cetuximab for colorectal cancer. later studies shall also have to validate whether this mutation con tributes to acquiri ng a resistance to cetuximab in tumors for which it is also used, such as head and throat cancer.”this study has been carried out in collaboration with researchers

13、from the genomic regulation centre (crg) from vail d'hebron research institute (vhir) and the genetech centre in the united states. the group is currently working to establish the prevale nee of the mutation and to see if it occurs also to patients with other tumors who are also treated with cet

14、uximab.identified a cause of resista nee to colon cancer treatmentthe work will be published in the latest issue of naturemedicine journal确定治疗结肠癌耐药的原因 这项研究将发表在最新一期的自然医学杂志doctors and researchers of hospital del mar and its research institute, the imim, have lead a study describing a new pharmacologic

15、al resista nee to cancer. this new mechanism is a mutation in an oncogene called egfr (epidermal growth factor receptor) causi ng resista nee to treatment using a drug called cetuximab, a monoclonal antibody which specifically attacks the egfr.来自德马医院(hospital del mar)及其研究所the imim的医工 和研究人员将描述一项结肠癌耐药

16、的药理学研究。这种新的机 制，是基因突变导致的耐药，而这个基因是表皮生长因子受体的 原癌基因。这个基因导致了对西妥昔单抗的耐药。而西妥昔单抗 是一个单克隆抗体，特异性的攻击表皮生长因子受体。the study proves that, both in lab models and in patients with colon cancer, this mutation appears during the disease and that, when this happens, it stops the drug from being effective and the tumor grows

17、. this finding will ben efit a large number of patients since colorectal cancer is the second most frequent tumor and cetuximab is a drug used regularly to treat this form of cancer.研究证明，无论是在实验室模型或者是结肠癌患者中，这种突变 贯穿于整个疾病中，以至于当这种突变发牛的时候，它就会降低 药物的有效性，最终导致肿瘤成长。这项发现将会使大量的患者 受益，这是因为大肠癌是个种常见的肿瘤。与此同时西妥昔单 抗是治

18、疗大肠癌的常用药物。also, another extremely relevant fact is that tumors acquire this mutation do respond to a treatment using another similar drug, called panitumumab, which is also available for clinical use. this carries im porta nt clinical implications, since it suggests the possibility of carrying out c

19、linical tests to confirm the effectiveness of panitumumab in patients with colon cancer who no ion ger resp ond to cetuximab, this increasi ng the range of therapies that may be used on patients with this cancer.此外，另-个极为相关的事实是，当肿瘤产生这种突变吋，他也 会对相似的药物产生耐药，这种机制可被临床运用.这项研究具 有重大的临床意义，因为它表明了一种可能性，那既是已经出现 对

20、帕尼单抗耐药的大肠癌患者对西妥昔单抗是否还具有效性，以 及是否会增加西妥昔单抗的疗程。the relevance of this study is also in the fact that it is the first time that a mutation is detected in the field of oncology in stead of a bond with the an tibody as a form of resista nee. therefore, it will be interesting to see whether there are other s

21、imilar mutatio ns causi ng resista nee to other pharmacological antibodies which are used frequently to treat other forms of cancer, such as breast cancer.这项研究是第次在肿瘤学发现是基因突变导致了耐药，而不是 一堆的抗体导致的耐夯。因此，这将会引起其他有相似耐药机制 的癌症研究的兴趣。比如帕尼单抗耐药的乳腺癌。therefore, this is a completely new mechanism of resista nee to a

22、drug used very often for a type of cancer with a high incidenee and relevant clinical implications for the treatment of patients with this type of cancer.因此，这是一个全新的癌症耐药的机制。尤其是临床上经常使用 帕尼单抗治疗的那-类癌症。”the discovery of this mutation may explain, at a molecular level, the benefits obtained by some patient

23、s with colon cancer treated with panitumumab and the inefficiency when treating with cetuximab” explains clara montagut, an associate doctor of the oncology service of hospital del mar and a researcher at imim, who has lead this study.“在分子水平，这个突变的发现可以解释临床上有的结肠癌病人 对帕尼单抗有效，而对西妥昔单抗没有效果。"claramonta

24、gut 解释道。clara montagut是德马医院肿瘤科的一个医生，德马医 院研究所的研究员，此项研究的主要参与者。colorectal cancer is the most frequent form of cancer in men and wome n and shows an in creasing incidence, and is the main cause of death by cancer when studying the cases in male and female patients jointly. however, over the past decade,

25、 treatme nt has bee n revolutionized with the introduction of new chemotherapy drugs and treatments targeti ng cellular targets, such as mono clonal antibodies or drugs used to treat colorectal cancer. dr. joan albanell, head of the medical oncologic service of hospital del mar and head of the resea

26、rch group and the author of the study, states that: 'this new type of mutation reveals one of the causes why cancer therapy with monoclonal antibodies may cease to be effective at a given moment and, especially, opens the door to looking for solutions."结肠癌是在男性及女性屮作常见的癌症，也是癌症患者最主要的 死亡原因。然而，过去十年屮，掀起了一场以使用化疗药物或者 以细胞为靶目标的治疗方案，比如说单克隆的抗体用于治疗结肠 癌。joanalbanell医生，德马医院肿瘤科主任，此研究课题负 责人，陈述道”这个新的突变揭示了单克隆抗体治疗癌症随着时 间推移越来越不管用的原因。以及打开了寻求解决办法的大门 dr. montagut con eludes by saying: 'these results